Agendia
18
4
4
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
11.1%
2 terminated/withdrawn out of 18 trials
84.6%
-1.9% vs industry average
11%
2 trials in Phase 3/4
9%
1 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS
Role: collaborator
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Role: collaborator
LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)
Role: collaborator
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Role: lead
Vinorelbine in Advanced BRAF-like Colon Cancer
Role: collaborator
Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk
Role: collaborator
The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer
Role: collaborator
Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes
Role: collaborator
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Role: lead
PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe)
Role: collaborator
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer
Role: collaborator
The Study of Molecular Risk Panels (70-gene Assay) in Chinese Breast Cancer Patients
Role: lead
A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint
Role: lead
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
Role: lead
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Role: lead
The Symphony Triple A Study: Using Symphony in Treatment Decisions Concerning Adjuvant Systemic Therapy
Role: collaborator
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Role: lead
Validation of 70-gene MammaPrint Profile in Japanese Population
Role: lead
All 18 trials loaded